<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255434</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC2016/27</org_study_id>
    <nct_id>NCT03255434</nct_id>
  </id_info>
  <brief_title>LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy</brief_title>
  <acronym>LEANOX</acronym>
  <official_title>LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytotoxic chemotherapy is usually scaled to the body surface area (BSA), and is currently not&#xD;
      adjusted to the body proportions of lean and fat (i.e. body composition) of individual&#xD;
      patients. Patients with low muscle mass behave like patients &quot;overdosed&quot; with chemotherapy&#xD;
      resulted in dose-limiting toxicities (e.g. dose reductions, treatment delays or permanent&#xD;
      treatment discontinuation), independently of the patient's weight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant chemotherapy with fluoropyrimidines and Oxaliplatin is the current worldwide&#xD;
      standard of care for stage III colorectal cancer (CRC). This regimen leads to significant&#xD;
      cost, toxicity, and patient inconvenience. Oxaliplatin induces two distinct forms of&#xD;
      neuropathy: a common acute syndrome that is transient (dysesthesia, contractures and&#xD;
      numbness) and a dose-limiting chronic sensory neurotoxicity that is cumulative. Neurotoxicity&#xD;
      is common; it affects 80% of patients and becomes chronic in 15-20% of cases, sometimes&#xD;
      irreversibly. Chronic neurotoxicity can severely affect everyday life activities. To date,&#xD;
      neuromodulators agents have failed to prevent neurotoxicity and Stop &amp; Go strategies,&#xD;
      intended to decrease the cumulative dose of Oxaliplatin administrated, are more appropriate&#xD;
      for palliative treatment of advanced CRC. Recent data support the plausibility of a shorter&#xD;
      duration of adjuvant treatment without loss of efficacy. This hypothesis is tested in several&#xD;
      international trials.&#xD;
&#xD;
      Cytotoxic chemotherapy is usually scaled to the body surface area (BSA), and is currently not&#xD;
      adjusted to the body proportions of lean and fat (i.e. body composition) of individual&#xD;
      patients. The impact of body composition on drug metabolism is however well known: i.e.&#xD;
      anesthetics accumulate in adipose tissue and specific precautions are essential to avoid&#xD;
      overdose. Concerning chemotherapies, the lean body mass (LBM) may be the salient feature&#xD;
      defining drug metabolism. A theme is emerging from recent studies: in patients with breast&#xD;
      cancer and treated with 5-FU (whose dosage was calculated from the body surface), severe&#xD;
      depletion of the LBM is a powerful predictor of excessive toxicity. Indeed, depletion of the&#xD;
      LBM, as precisely defined by computed tomography, is a unique predictor of clinically&#xD;
      unacceptable toxicity. Low LBM was shown to be a significant predictor of dose-limiting&#xD;
      toxicity (DLT) in CRC patients administered 5-FU using a conventional BSA-based dosing and&#xD;
      DLT was concentrated in patients receiving &gt;20 mg 5FU/kg LBM. Two cohorts of CRC patients&#xD;
      treated with Oxaliplatin showed that overall DLTs, and specifically Oxaliplatin-due&#xD;
      neuropathy, occurred mostly in patients who receive &gt; 3.09 mg/Oxaliplatin/kg LBM. Although,&#xD;
      preliminary findings are available in hepatocellular carcinoma, the area under the&#xD;
      concentration time curve (AUC) of Sorafenib cancer therapy was doubled in patients with&#xD;
      depleted LBM (102.4 vs. 53.7ng/mL.h), which seem of interest. Patients with low muscle mass&#xD;
      behave like patients &quot;overdosed&quot; with chemotherapy resulted in dose-limiting toxicities (e.g.&#xD;
      dose reductions, treatment delays or permanent treatment discontinuation), independently of&#xD;
      the patient's weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of neurotoxicity associated with Oxaliplatin</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Neurotoxicity assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Stage III Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Folfox 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folfox 4 LBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12</description>
    <arm_group_label>Folfox 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin LBM</intervention_name>
    <description>Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2</description>
    <arm_group_label>Folfox 4 LBM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: more than 18 years old up to 75 years old including. Histologically confirmed&#xD;
             adenocarcinoma of the colon.&#xD;
&#xD;
          -  Has undergone a curative resection for stage III colon cancer.&#xD;
&#xD;
          -  Scheduled to receive 6 months of Oxaliplatin-based adjuvant chemotherapy at a dose of&#xD;
             85 mg/m² of Oxaliplatin every 2 weeks (simplified FOLFOX 4 regimen).&#xD;
&#xD;
          -  The following laboratory values obtained ≤ 28 days prior to inclusion:&#xD;
&#xD;
        WBC ≥ 3000/mm3; ANC ≥1500/mm3; PLT ≥100,000/mm3; HgB ≥10.0g/dl; Total bilirubin ≤1.5 x&#xD;
        upper normal limit (UNL); Serum creatinine ≤1.5 x UNL; Serum calcium ≤ 1.2 x UNL; Serum&#xD;
        magnesium ≤ 1.2 x UNL.&#xD;
&#xD;
          -  Central venous access line present or patient scheduled to have a central line placed&#xD;
             prior to starting chemotherapy or the treatment protocol.&#xD;
&#xD;
          -  Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for&#xD;
             women of childbearing potential only.&#xD;
&#xD;
          -  Ability to complete questionnaire(s) by themselves or with assistance.&#xD;
&#xD;
          -  ECOG Performance Status (PS) of 0, 1 for patients until 70 years old included and ECOG&#xD;
             PS of 0 for patients between 70 to 75 years old included.&#xD;
&#xD;
          -  Has provided informed written consent.&#xD;
&#xD;
          -  Patient willing to provide blood sample for research purposes&#xD;
&#xD;
          -  Patient affiliated to a French social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
             contraception since this study involves agents that have known genotoxic, mutagenic&#xD;
             and teratogenic effects&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy of any grade.&#xD;
&#xD;
          -  Prior treatment with neurotoxic chemotherapy such as Oxaliplatin, cisplatin, taxanes,&#xD;
             or vinca alkaloids.&#xD;
&#xD;
          -  Treatment with 1) the anticonvulsants carbamazepine (e.g., Tegretol®), phenytoin&#xD;
             (e.g., Dilantin®), valproic acid (e.g. Depakine®), gabapentin (Neurontin®); pregabalin&#xD;
             (Lyrica®); 2) the following neurotropic agents: venlafaxine (Effexor®), desvenlafaxine&#xD;
             (Pristiq®), milnacipran (Savella®) or duloxetine (Cymbalta®); 3) Tricyclic&#xD;
             antidepressants (such as amitryptilline) or 4) any other agent specifically given to&#xD;
             prevent or treat neuropathy.&#xD;
&#xD;
          -  Family history of a genetic/familial neuropathy.&#xD;
&#xD;
          -  Participation in another medication trial within 30 days prior to study entry&#xD;
&#xD;
          -  Legal incapacity or physical, psychological social or geographical status interfering&#xD;
             with the patient's ability to sign the informed consent or to terminate the study&#xD;
&#xD;
          -  History of other solid tumor in 3 years before the inclusion, excepted of cancer in&#xD;
             situ of the cervix and skin cancer (basal or squamous cell) treated and controlled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marc YCHOU</last_name>
    <role>Study Director</role>
    <affiliation>Institut régional du Cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>eric ASSENAT</last_name>
    <phone>+33467603102</phone>
    <email>eric.assenat@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <state>Bouches Du Rhône</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Rinaldi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves Rinaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional et universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Assenat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Assenat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Lorraine</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Lopez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Meurthe-et-Moselle,</state>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelien Lambert, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurelien Lambert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Jean</name>
      <address>
        <city>Perpignan</city>
        <state>Pyrénées-orientales</state>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Khemissa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Faiza Khemissa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre GALAIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Pierre GALAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois Seitz, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Francois Seitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut regional du Cancer - Val d Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bleuse Jean-Pierre</last_name>
      <phone>+33467612344</phone>
      <email>jean-pierre.bleuse@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>assenat eric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas APARICIO, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Thomas APARICIO, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Lievre</last_name>
    </contact>
    <investigator>
      <last_name>Astrid Lievre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher Ben Abdelghani</last_name>
    </contact>
    <investigator>
      <last_name>Meher Ben Abdelghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

